Torisel, Sutent, Nexavar Combinations Are “Future” Of RCC Treatment – Wyeth Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth plans to look at drug combinations in the kidney cancer arena using its renal cell carcinoma candidate Torisel.
You may also be interested in...
Sutent Labeling Updated To Reflect First-Line Renal Cell Carcinoma Data
Study showed sunitinib more than doubled progression-free survival over interferon-alfa.
Sutent Labeling Updated To Reflect First-Line Renal Cell Carcinoma Data
Study showed sunitinib more than doubled progression-free survival over interferon-alfa.
Wyeth Submits NDA For Temsirolimus In Kidney Cancer
Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.